Cognitive therapy for body dysmorphic disorder

Not Applicable

Completed

• Conditions: Mental and Behavioural Disorders; Body dysmorphic disorder; Hypochondriacal disorder

• Registration Number: ISRCTN92515063
• Lead Sponsor: Deutsche Forschungsgemeinschaft (DFG)

Brief Summary

2022 Results article in https://doi.org/10.1016/j.beth.2022.07.006 (added 14/10/2022)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2017-05-12
• Study Completion: 2021-03-01
• Last Update Posted: 24 October 2022

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

1. Primary diagnosis of body dysmorphic disorder (BDD) according to the Body Dysmorphic Disorder Diagnostic Module (BDDDM adapted for DSM-5), the Structured Interview for Diagnostic and Statistical Manual of Mental Disorders – Fifth Edition (SCID-I DSM-5) and the Yale-Brown Obsessive-Compulsive Scale Modified for BDD (BDD-YBOCS) = 20
2. BDD symptoms for at least 6 months prior to participation
3. Age 18-70 years
4. Either no psychotropic medication or, if taking psychotropic medication, be on a stable dose for at least 2 months prior to initial evaluation and agreement not to change the medication during the study
5. Written informed consent

Exclusion Criteria

1. Acute suicidality
2. Psychotic disorder (excluding delusional BDD)
3. Bipolar disorder
4. Alcohol or substance dependence within the last 3 months
5. Borderline personality disorder
6. Prominent risk of self-harm
7. Body image/weight concerns accounted primarily by an eating disorder
8. Organic mental disorder
9. Severe medical conditions
10. Concurrent psychotherapeutic treatment (e.g., psychodynamic)

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<br> For A1:<br> 1. BDD symptom severity, measured using the clinician-administered Body Dysmorphic Disorder Modification of the Yale-Brown Obsessive-Compulsive Scale (BDD-YBOCS)<br> 2. BDD diagnosis, measured using the clinician-administered BDD Diagnostic Module (BDDDM)<br> Measured at pretreatment, 12 weeks/post-WL, 24 weeks, post treatment, 3- and 6-months follow-up<br>